Lara Hathout, MD, FRCPC

I am an Associate Professor of Radiation Oncology and Director of Brachytherapy at the Rutgers Cancer Institute of New Jersey (CINJ). I completed a Brachytherapy Fellowship at the Memorial Sloan-Kettering Cancer Center in June 2014 after completing my medical training and residency in Radiation Oncology at University of Montreal in Montreal, Canada. Before joining Rutgers CINJ in 2016, I was a Clinical Instructor in the Department of Radiation Oncology at CHU de Quebec, Quebec City, Canada.

My clinical sites are GYN and GU cancers. Since Rutgers CINJ is the only institution in New Jersey offering interstitial HDR GYN brachytherapy, I run a high-volume brachytherapy service in addition to offering patients leading-edge technology including Stereotactic Body radiotherapy and Proton Beam Therapy. I speak several languages fluently including French and Spanish.

I am a reviewer of the Brachytherapy Journal, the Advances in Radiation Oncology and the Practical Radiation Oncology Journal, abstract reviewer for the Annual ASTRO Meeting for GYN track and Annual ABS Meeting for GU track. I am a member of the ASTRO History and Guidelines subcommittees.

I was awarded the Abbvie-CARO Uro-oncologic Radiation Award (ACURA) in 2015 for a phase II prospective trial evaluating acute and late toxicity of LDR Brachytherapy and HDR brachytherapy for localized prostate cancer. The results were presented at National meetings and the manuscript was published. I developed an investigator-initiated trial comparing SBRT to HDR brachytherapy for prostate cancer. The trial is open and accruing.

Complete List of Published Work in My Bibliography:

https://www.ncbi.nlm.nih.gov/pubmed/?term=lara+hathout

Disclosures: